| Event | Date |
|---|---|
| Open Date | 20-02-2026 , Friday |
| Close Date | 24-02-2026 , Tuesday |
| Tentative Allotment | 25-02-2026 , Wednesday |
| Tentative Listing Date | 27-02-2026 , Friday |
| Retail Appl. Cut Off Time | 24-02-2026 , Tuesday 05:00 PM |
| Non Retail Appl. Cut Off Time | 24-02-2026 , Tuesday 04:00 PM |
| Anchor Allotment | 18-02-2026 , Wednesday |
| Initiation Of Refund | 25-02-2026 , Wednesday |
| Credit Of Share To Demat | 26-02-2026 , Thursday |
Gaudium IVF and Women Health Limited is engaged in fertility and reproductive healthcare services, mainly focused on IVF treatment, related women’s health services, hospital support and pharmacy services. The company operates through a hub-and-spoke model and provides fertility care across multiple Indian locations.
Gaudium IVF and Women Health Limited is an IVF and women’s healthcare company incorporated in 2015. The company provides fertility treatments and related reproductive healthcare services for couples facing infertility, medical complications or lifestyle-related reproductive health challenges.
The company was founded by Dr. Manika Khanna and has built its operations around IVF treatment, women’s healthcare, hospital support and pharmacy services. Its business includes patient consultation, diagnosis, treatment planning, IVF procedures, pregnancy support and related medical support.
IVF treatment and fertility healthcare services remain the company’s main business area.
The company follows a hub-and-spoke model to expand reach while centralising advanced treatment infrastructure.
Revenue comes from IVF treatment, hospital services and pharmacy services.
The company offers a range of fertility and reproductive health services. The main services include IVF treatment, IUI, ICSI, PCOS / PCOD treatment, male infertility treatment, endometriosis treatment, ovulation induction, laser assisted embryo implantation, infertility surgeries and medical support for surrogacy-related treatment.
IVF means In Vitro Fertilization. It is a fertility treatment where eggs are collected from the woman and fertilised with sperm in a laboratory. The embryo is then transferred into the uterus.
IUI means Intrauterine Insemination. In this procedure, selected healthy sperm are placed directly inside the uterus to improve the chance of fertilisation.
ICSI means Intracytoplasmic Sperm Injection. A single healthy sperm is directly injected into a mature egg, generally useful in male infertility cases.
PCOS means Polycystic Ovarian Syndrome and PCOD means Polycystic Ovarian Disease. These hormonal conditions may affect ovulation and fertility.
The company provides treatment support for sperm disorders, hormonal imbalance and other male infertility conditions.
The company also earns revenue from hospital services and pharmacy services through Gaudium International Private Limited.
Gaudium IVF earns revenue mainly from three service areas: IVF Treatment, Hospital services and Pharmacy services. IVF Treatment continues to be the largest contributor, while Pharmacy revenue has increased significantly in the latest period.
| Services Offered | Period ended September 30, 2025 | % of Revenue from Operations | Fiscal 2025 | % of Revenue from Operations | Fiscal 2024 | % of Revenue from Operations | Fiscal 2023 | % of Revenue from Operations |
|---|---|---|---|---|---|---|---|---|
| IVF Treatment | Rs. 3,393.34 lakhs | 68.55% | Rs. 5,554.38 lakhs | 78.54% | Rs. 4,222.43 lakhs | 88.17% | Rs. 4,015.24 lakhs | 90.77% |
| Hospital | Rs. 128.55 lakhs | 2.60% | Rs. 345.78 lakhs | 4.89% | Rs. 371.39 lakhs | 7.75% | Rs. 386.19 lakhs | 8.73% |
| Pharmacy | Rs. 1,427.99 lakhs | 28.85% | Rs. 1,172.24 lakhs | 16.57% | Rs. 195.20 lakhs | 4.08% | Rs. 22.26 lakhs | 0.50% |
| Total | Rs. 4,949.88 lakhs | 100.00% | Rs. 7,072.40 lakhs | 100.00% | Rs. 4,789.01 lakhs | 100.00% | Rs. 4,423.69 lakhs | 100.00% |
Note: Gaudium International Private Limited, a pharmaceutical business, was acquired by the company pursuant to a Share Purchase Agreement dated February 2, 2023. As a result of this acquisition, Gaudium International Private Limited became a wholly owned subsidiary of the company.
IVF Treatment is still the company’s core business, but Pharmacy revenue has increased sharply in the latest period. Pharmacy revenue increased from only 0.50% in Fiscal 2023 to 28.85% for the period ended September 30, 2025. This improves revenue diversification, but investors should also understand whether this pharmacy growth is sustainable and whether pharmacy margins are comparable with IVF service margins.
The company’s IVF service journey can be understood in three broad parts: conversion of lead, IVF process and hospital support.
Patient onboarding is an important operating metric for an IVF company because revenue depends on patient inflow, conversion into treatment, number of cycles and average realisation per patient.
| Fiscal / Period | Number of Patients |
|---|---|
| Period ended September 30, 2025 | 1,315 |
| Fiscal 2025 | 1,563 |
| Fiscal 2024 | 2,229 |
| Fiscal 2023 | 1,167 |
Patient onboarding increased strongly from Fiscal 2023 to Fiscal 2024, but reduced in Fiscal 2025. Investors should check whether this was due to centre-level changes, pricing, competition, marketing efficiency, patient conversion rate or any other operational factor.
The company has reported strong operating margins in the latest periods. However, margins have moved compared with Fiscal 2023, so investors should study the reasons behind margin movement carefully.
| Particulars | Period ended September 30, 2025 | Fiscal 2025 | Fiscal 2024 | Fiscal 2023 |
|---|---|---|---|---|
| Revenue from Operations | Rs. 4,949.88 lakhs | Rs. 7,072.40 lakhs | Rs. 4,789.01 lakhs | Rs. 4,423.69 lakhs |
| Total Revenue | Rs. 4,974.97 lakhs | Rs. 7,095.84 lakhs | Rs. 4,815.31 lakhs | Rs. 4,426.02 lakhs |
| EBITDA | Rs. 1,895.23 lakhs | Rs. 2,862.59 lakhs | Rs. 1,927.47 lakhs | Rs. 2,006.55 lakhs |
| EBIT | Rs. 1,778.60 lakhs | Rs. 2,681.34 lakhs | Rs. 1,737.91 lakhs | Rs. 1,865.48 lakhs |
| EBT | Rs. 1,678.29 lakhs | Rs. 2,542.25 lakhs | Rs. 1,663.16 lakhs | Rs. 1,831.24 lakhs |
| PAT | Rs. 1,250.56 lakhs | Rs. 1,912.74 lakhs | Rs. 1,031.69 lakhs | Rs. 1,352.54 lakhs |
| EBITDA Margin | 38.29% | 40.48% | 40.25% | 45.36% |
| EBIT Margin | 35.75% | 37.79% | 36.09% | 42.15% |
| EBT Margin | 33.73% | 35.83% | 34.54% | 41.37% |
| PAT Margin | 25.14% | 26.96% | 21.43% | 30.56% |
| Debt / Equity | 0.38 | 0.41 | 0.58 | 0.43 |
| RoE | 21.25% | 41.31% | 38.23% | 59.51% |
| RoCE | 21.03% | 39.37% | 38.74% | 54.40% |
| Basic EPS | Rs. 2.04 | Rs. 3.12 | Rs. 1.68 | Rs. 2.20 |
| Diluted EPS | Rs. 2.04 | Rs. 3.12 | Rs. 1.68 | Rs. 2.20 |
| NAV | Rs. 9.59 | Rs. 7.54 | Rs. 4.40 | Rs. 3.70 |
Note: Figures are not annualized where applicable.
Gaudium IVF follows a hub-and-spoke model. Hub centres provide advanced IVF and reproductive healthcare procedures, while spoke locations support awareness, consultation, patient outreach and patient referral to hub centres where advanced treatment is required.
Hub centres are equipped for advanced IVF procedures, consultation, laboratory support and specialist-led fertility treatment.
Spoke locations help in patient reach, awareness building, consultation and routing suitable cases to the hub centres.
In Vitro Fertilization
Intrauterine Insemination
Intracytoplasmic Sperm Injection
Ovum Pick Up
Embryo Transfer
Polycystic Ovarian Syndrome
Polycystic Ovarian Disease
Earnings Before Interest, Tax, Depreciation and Amortisation
Profit After Tax
This content is prepared only for educational and informational purposes based on details available from the company’s RHP and related disclosures. IPORupee does not provide any buy, sell, apply or avoid recommendation for this IPO. The information should not be treated as investment advice, research advice, medical advice or financial advice.
Investors should read the full RHP, risk factors, objects of the issue, financial statements, legal proceedings and all relevant disclosures carefully before making any investment decision. Please consult your SEBI-registered investment advisor or financial advisor before investing.
| Category | Percentage | No. of Shares Offered | Amount |
|---|---|---|---|
QIB | 50.00 % | 1,04,43,100 | 82.50 Cr |
Retail | 35.00 % | 73,10,170 | 57.75 Cr |
Total HNI | 15.00 % | 31,32,930 | 24.75 Cr |
SHNI | 5.00 % | 10,44,310 | 8.25 Cr |
BHNI | 10.00 % | 20,88,620 | 16.50 Cr |
Gaudium IVF and Women Health Ltd allotted 62,65,860 equity shares to anchor investors at ₹79 per share on 18 Feb 2026 before the IPO opening. The total anchor allocation stood at 49.50 Cr across 4 anchor investors.
The largest anchor investor received 34.34% of the anchor portion. The top five anchor investors together received 62,65,860 shares, representing about 100.00% of the total anchor allocation.
| Rank | Anchor Investor Name | Shares Allocated | Allocation % | Allocation Amount |
|---|---|---|---|---|
| 1 | MERU Investment Fund PCC-CELL 1 | 21,51,330 | 34.34 % | 17.00 Cr |
| 2 | Sanshi Fund I | 15,82,308 | 25.25 % | 12.50 Cr |
| 3 | Hornbill Orchid India Fund | 12,66,300 | 20.21 % | 10.00 Cr |
| 4 | Carnelian India Multi Strategy Fund | 12,65,922 | 20.20 % | 10.00 Cr |
The figures are based on the company’s stock exchange anchor allotment intimation. Anchor allocation is only an informational disclosure and does not indicate future listing performance.
| Application | Discount | Qty (Lot) | Total |
|---|---|---|---|
Retail MIN | - | 189 (1) | ₹ 14,931 |
Retail MAX | - | 2457 (13) | ₹ 1,94,103 |
SHNI MIN | - | 2646 (14) | ₹ 2,09,034 |
SHNI MAX | - | 12474 (66) | ₹ 9,85,446 |
BHNI MIN | - | 12663 (67) | ₹ 10,00,377 |
| Particulars | 30 Sep, 2025 | 31 Mar, 2025 | 31 Mar, 2024 | 31 Mar, 2023 |
|---|---|---|---|---|
Revenue from Operation | 49.50 | 70.72 | 47.89 | 44.24 |
Other Income | 0.25 | 0.23 | 0.26 | 0.02 |
Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
Total Expenses | 32.97 | 45.54 | 31.52 | 25.95 |
Operating Profit | 16.78 | 25.42 | 31.52 | 25.95 |
Exceptional Items | - | - | - | - |
Profit Before Tax | 16.78 | 25.42 | 31.52 | 25.95 |
Profit Before Tax | - | - | - | - |
Tax | 4.28 | 6.30 | 6.32 | 4.79 |
Net Profit | 12.51 | 19.13 | 10.32 | 13.53 |
Basic EPS In Rs. | 2.04 | 3.12 | 1.68 | 2.20 |
Diluted EPS In Rs. | 2.04 | 3.12 | 1.68 | 2.20 |
| Particulars | 30 Sep, 2025 | 31 Mar, 2025 | 31 Mar, 2024 | 31 Mar, 2023 |
|---|---|---|---|---|
Property Plant and Equipment | 6.80 | 6.41 | 5.79 | 3.79 |
Right of Use Asset | 1.34 | 1.46 | 1.56 | 1.75 |
Goodwill | 0.37 | 0.37 | 0.37 | 0.37 |
Other Intangible Assets | 9.29 | 9.88 | 10.96 | 12.14 |
Intangible Assets Under Development | 11.97 | 7.39 | 0.13 | 0.13 |
Financial Assets | 9.20 | 9.20 | 0.17 | 0.05 |
Other Non Current Assets | - | - | 2.50 | - |
Total Non Current Assets | 38.96 | 34.71 | 21.49 | 18.24 |
Inventories | 4.82 | 7.23 | 2.10 | 1.50 |
Financial Assets | 59.34 | 42.65 | 26.87 | 16.47 |
Other Current Assets | 3.50 | 3.92 | 0.55 | 0.42 |
Total Current Assets | 67.66 | 53.81 | 29.52 | 18.39 |
Total Assets | 106.62 | 88.51 | 51.01 | 36.63 |
Equity Share Capital | 30.70 | 30.70 | 0.99 | 0.99 |
Other Equity | 28.16 | 15.60 | 26.00 | 21.74 |
Total Eauity | 58.86 | 46.30 | 26.99 | 22.73 |
Financial Liabilities | 18.86 | 3.22 | 3.49 | 3.78 |
Provisions | 0.38 | 0.36 | 0.38 | 0.51 |
Deferred Tax Liabilities (Net) | 0.66 | 0.62 | 0.46 | 0.01 |
Total Non Current Liabilities | 19.90 | 4.20 | 4.33 | 4.30 |
Financial Liabilities | 18.55 | 31.36 | 14.69 | 8.80 |
Other Current Liabilities | 1.31 | 0.98 | 0.90 | 0.74 |
Provision | 0.15 | 0.15 | 0.02 | 0.02 |
Current Tax Liabilities | 7.85 | 5.53 | 4.08 | 0.04 |
Total Current Liabilities | 27.87 | 38.01 | 19.69 | 9.30 |
Total Equity and Liabilities | 106.62 | 88.51 | 51.01 | 36.63 |
| Particulars | 30 Sep, 2025 | 31 Mar, 2025 | 31 Mar, 2024 | 31 Mar, 2023 |
|---|---|---|---|---|
Cash Flow From Operating Activities | 2.356 | 8.718 | 3.441 | 23.853 |
Cash Flow From Investing Activities | -5.441 | -15.174 | -5.402 | -15.627 |
Cash Flow From Financing Activities | 2.489 | 1.817 | -1.241 | 5.255 |
Net Cash Flow | -0.596 | -4.64 | -3.202 | 13.481 |
| KPI | H1 30 Sep, 2025 | Fiscal 2025 | Fiscal 2024 | Fiscal 2023 |
|---|---|---|---|---|
Revenue from Operations | 49.50 | 70.72 | 47.89 | 44.24 |
Total Revenue | 49.75 | 70.96 | 48.15 | 44.26 |
EBITDA | 18.95 | 28.63 | 19.28 | 20.07 |
EBIT | 17.79 | 26.81 | 17.38 | 18.66 |
EBT | 16.78 | 25.42 | 16.63 | 18.31 |
PAT | 12.51 | 19.13 | 10.32 | 13.53 |
EBITDA Margin (in %) | 38.29 | 40.48 | 40.25 | 45.36 |
EBIT Margin (in %) | 35.75 | 37.79 | 36.09 | 42.15 |
EBT Margin (in %) | 33.73 | 35.83 | 34.54 | 41.37 |
PAT Margin (in %) | 25.14 | 26.96 | 21.43 | 30.56 |
Debt/Equity Ratio | 0.38 | 0.41 | 0.58 | 0.43 |
ROE (in %) | 21.25 | 41.31 | 38.23 | 59.51 |
ROCE (in %) | 21.03 | 39.37 | 38.74 | 54.40 |
Basic EPS (In ₹) | 2.04 | 3.12 | 1.68 | 2.20 |
Diluted EPS (In ₹) | 2.04 | 3.12 | 1.68 | 2.20 |
NAV (In ₹) | 9.59 | 7.54 | 4.40 | 3.70 |
| Objective | No Of Shares | Amount |
|---|---|---|
Fresh Issue | 1,13,92,500 | 90.00 Cr |
Offer for Sale | 94,93,700 | 75.00 Cr |
| # | Title | Published Date |
|---|---|---|
| 1 | Gaudium IVF & Women Health IPO Review: Key Details, Company Overview, Industry Context | 18-02-2026 , Wednesday |
| Name | Contact Person | Telephone | Website | |
|---|---|---|---|---|
Sarthi Capital Advisors Private Limited | Pankaj Chaurasia | +91 22 2652 8671/ 72 | ipo@sarthiwm.in | www.sarthi.in |
Understand company details, IPO size, price band, lot size, exchange listing, fresh issue and Offer for Sale (OFS) in simple language for retail investors.
This IPO is of Gaudium IVF and Women Health Ltd. The issue is scheduled to open on Friday, 20 February 2026 and closes on Tuesday, 24 February 2026.
After the IPO process is completed, the shares are proposed to be listed on both NSE and BSE.
IPO size means the total amount offered to investors through the public issue.
For Gaudium IVF and Women Health Ltd IPO, the total issue size is Rs 165 crore, consisting of a fresh issue of Rs 90 crore and an Offer for Sale (OFS) of Rs 75 crore.
Price band is the price range within which investors can bid for shares in a book-built IPO.
For this IPO, the lower price band is Rs 75 per share and the upper price band is Rs 79 per share.
Lot size is the minimum number of shares an investor must apply for in an IPO. IPO applications are usually made in fixed lot multiples.
For Gaudium IVF and Women Health Ltd IPO, the minimum lot size is 189 shares. At the upper price band of Rs 79 per share, the minimum application amount is Rs 14,931. Applications must be made in multiples of 189 shares.
Fresh Issue means the company issues new shares to investors and receives money from that part of the IPO.
For Gaudium IVF and Women Health Ltd IPO, the Fresh Issue size is Rs 90 crore. The company can use these funds for purposes mentioned in the IPO documents, such as business growth, repayment of borrowings, working capital, capital expenditure, or general corporate purposes.
Offer for Sale (OFS) means existing shareholders sell their shares to the public through the IPO.
For Gaudium IVF and Women Health Ltd IPO, the Offer for Sale (OFS) size is Rs 75 crore. In an OFS, the selling shareholders receive the money, and the company usually does not receive funds from that portion.
Understand the important IPO dates, allotment process, refund schedule and listing timeline in a retail-friendly format.
The IPO opening date is the first day on which investors can apply for the public issue.
For Gaudium IVF and Women Health Ltd IPO, the IPO opens on Friday, 20 February 2026.
The IPO closing date is the last day on which investors can submit, modify, or cancel their IPO applications.
Gaudium IVF and Women Health Ltd IPO closes on Tuesday, 24 February 2026.
The tentative allotment date is the expected date on which the registrar finalizes the share allotment for valid IPO applications.
For Gaudium IVF and Women Health Ltd IPO, the tentative allotment date is Wednesday, 25 February 2026.
The tentative listing date is the expected date on which IPO shares begin trading on the stock exchanges.
Gaudium IVF and Women Health Ltd IPO is expected to list on Friday, 27 February 2026.
After allotment, funds are unblocked or refunds are initiated for non-allotted investors, while allotted shares are credited to investors' demat accounts before listing.
For Gaudium IVF and Women Health Ltd IPO, refund initiation is expected on Wednesday, 25 February 2026, and credit of shares to demat accounts is expected on Thursday, 26 February 2026.
Understand IPO category-wise reservation, QIB quota, retail quota, HNI allocation, shareholder reservation and the meaning of structure columns in a simple format.
IPO structure shows how shares are divided among different categories of investors, such as QIB, Retail, NII/HNI, Employees, and Shareholders.
For Gaudium IVF and Women Health Ltd IPO, the available categories in the structure table include QIB, Retail, Non-Institutional Investors (NII/HNI). The NII/HNI category includes SHNI and BHNI sub-categories. Investors can use this table to understand category-wise allocation before applying.
QIB stands for Qualified Institutional Buyers. This category includes mutual funds, banks, insurance companies, and other large financial institutions.
In Gaudium IVF and Women Health Ltd IPO, 50% shares are reserved under the QIB category, with 1,04,43,100 shares offered, and an allocation amount of ₹82.50 crore.
The Retail category is reserved for individual investors and HUFs applying for up to Rs 2 lakh within the retail investment limit allowed under IPO rules.
In Gaudium IVF and Women Health Ltd IPO, 35% shares are reserved under the Retail category, with 73,10,170 shares offered, and an allocation amount of ₹57.75 crore.
NII/HNI stands for Non-Institutional Investors / High Net-Worth Individuals. This category generally includes investors applying for more than Rs 2 lakh, above the retail investment limit.
In Gaudium IVF and Women Health Ltd IPO, 15% shares are reserved under the NII/HNI category, with 31,32,930 shares offered, and an allocation amount of ₹24.75 crore.
SHNI stands for Small HNI. It is a sub-category within the NII/HNI category and generally refers to applications for more than Rs 2 lakh but not exceeding Rs 10 lakh.
In Gaudium IVF and Women Health Ltd IPO, 5% shares are reserved under the SHNI sub-category, with 10,44,310 shares offered, and an allocation amount of ₹8.25 crore.
BHNI stands for Big HNI. It is a sub-category within the NII/HNI category and generally refers to applications for more than Rs 10 lakh.
In Gaudium IVF and Women Health Ltd IPO, 10% shares are reserved under the BHNI sub-category, with 20,88,620 shares offered, and an allocation amount of ₹16.50 crore.
Understand retail lot size, HNI application limits, employee category, shareholder category and investment amount calculations using the IPO lot table.
Lot size is the minimum number of shares an investor must apply for in an IPO. IPO applications are usually made in fixed lot multiples.
For Gaudium IVF and Women Health Ltd IPO, the minimum lot size is 189 shares. At the upper price band of Rs 79 per share, the minimum application amount is Rs 14,931. Applications must be made in multiples of 189 shares.
Retail minimum application shows the minimum application size for retail investors.
For Gaudium IVF and Women Health Ltd IPO, the Retail minimum application is 189 shares (1 lot) for about Rs 14,931.
Retail maximum application shows the maximum application size generally available under the retail category.
For Gaudium IVF and Women Health Ltd IPO, the Retail maximum application is 2,457 shares (13 lots) for about Rs 1,94,103.
SHNI minimum application shows the minimum application size for the Small HNI category.
For Gaudium IVF and Women Health Ltd IPO, the SHNI minimum application is 2,646 shares (14 lots) for about Rs 2,09,034.
SHNI maximum application shows the maximum application size available under the Small HNI category, when provided.
For Gaudium IVF and Women Health Ltd IPO, the SHNI maximum application is 12,474 shares (66 lots) for about Rs 9,85,446.
BHNI minimum application shows the minimum application size for the Big HNI category.
For Gaudium IVF and Women Health Ltd IPO, the BHNI minimum application is 12,663 shares (67 lots) for about Rs 10,00,377.
Understand important financial figures in simple language using the financial statement data available for the IPO.
Financial Highlights show important numbers from the company's financial statements. These may include income, expenses, profit, assets, liabilities, cash flow and other financial information, depending on the data available for the IPO.
The table displays available financial data based on the IPO information currently available. Fields may differ from company to company depending on disclosures and reporting format.
Investors should read the table to understand the company's financial performance and financial position over different periods.
The table may help users review income, expenses, profitability, balance sheet position, cash movement or other financial information, depending on the available data.
Financial statement line items may differ because companies operate in different industries and may follow different reporting formats.
Some companies may provide detailed financial breakup, while others may present broader financial categories.
Investors should review income, expenses, profitability, debt position, asset base, liabilities and cash flow position together.
A single financial figure should not be used alone to judge the company.
Profit is important, but it does not show the full financial picture.
Investors should also review revenue quality, expenses, debt, assets, liabilities, cash flow, valuation and business risks.
Cash flow helps investors understand how money moves in and out of the business.
A company may report profit but still face cash flow pressure, so cash flow should be reviewed along with profit, debt and balance sheet information.
No. Financial Highlights are useful, but investors should also review valuation, peer comparison, KPI data, business risks, IPO pricing, management discussion and official offer documents such as the RHP or DRHP.
Understand how the company may be compared with similar businesses using the peer comparison data available for the IPO.
Peer Comparison means comparing the IPO company with businesses operating in a similar sector or industry.
It helps investors understand the company in a broader industry context.
Peer Comparison helps investors understand how the company can be compared with similar businesses using available financial or valuation metrics.
It is useful for context, but it should not be treated as a final investment conclusion.
Peer comparison metrics may differ depending on the companies selected, accounting format, business model and available public information.
Investors should compare only relevant and similar metrics.
Investors should use the peer comparison table as a reference point.
Available metrics should be read together with business model, scale, profitability, margins, debt, growth, valuation and IPO pricing.
No. Peer Comparison does not directly decide whether an IPO is good or bad.
It only provides context for comparison. Final analysis should include financial statements, KPI data, valuation, risk factors and official offer documents.
No. Peer Comparison is only one part of IPO analysis.
Investors should also review financial statements, KPI data, business risks, valuation, IPO pricing and company fundamentals.
Understand important KPI metrics in simple language using the key performance indicator data available for the IPO.
Key Performance Indicators, or KPIs, are financial and valuation metrics used to understand profitability, efficiency, leverage, return-based ratios and earnings performance.
They help investors understand the company beyond basic financial figures.
KPIs help investors assess profitability, capital efficiency, leverage, valuation and earnings quality.
They should be reviewed together with financial statements, peer comparison and IPO pricing.
KPI data may differ depending on the company, industry, financial disclosures and available offer document information.
Not every IPO may provide every KPI, and some metrics may not be applicable to every business.
Investors should read KPI metrics together instead of relying on one ratio.
A single KPI may not give the full picture unless it is reviewed with financial statements, peer comparison, business model and valuation.
No. High or low KPI values need context.
The meaning of a ratio may differ depending on industry, business model, debt level, growth stage, profitability and IPO valuation.
No. KPI data is useful, but it should not be used alone.
Investors should also review financial statements, peer comparison, business risks, valuation, IPO pricing and official offer documents such as the RHP or DRHP.